Objective      To determine the effect of controlling glycosylated hemoglobin A1c (HbA1c) level and applying insulin on the cognitive function in the patients with type 2 diabetes based on the Montreal Cognitive Assessment Scale.       Methods      A total of 102 type 2 diabetes out-

and in-patients in our department from April 2012 to November 2012 were recruited in this study. They were 55 males and 47 females

at a mean age of 56.80±10.85

with an educational level of 10.20±3.71 years and a diabetic duration of 7.88±6.99 years. According to the American Diabetes Association recommended in 2010 that controlling HbA1c under 7% in type 2 diabetes can reduce the capillaries and neurological complications

these patients were divided into HbA1c ≤7% group (n=52) and HbA1c 7% group (n=50). In order to further study the benefit of insulin on cognitive function in type 2 diabetes

the patients were also divided into insulin treatment group (n=63)

and the untreatment group (n=39). Montreal Cognitive Assessment

Trail making test B

Hamilton Depression Scale

and Hamilton Anxiety Scale were used to evaluate the neuropsychological cognitive function in the patients.       Results      The HbA1c7% group had a higher incidence of diabetic angiopathy and neuropathy than the HbA1c≤7% group (

P

0.05). The HbA1c≤7% group had a score of 3.83±0.92 in view space

2.62±0.49 in clock draw

and 5.79±0.67 in direction in Montreal Cognitive Assessment Scale

and the HbA1c≤7% group had a score of 3.32±1.25

2.34±0.82

and 5.40±0.86 respectively for above parameters

with those of the former group significantly higher than those of the latter (

P

0.05). The insulin untreatment group took (250.33±73.16)s in trail making test B

and the insulin treatment group only took (220.75±85.11)s

with the former spend significantly longer time than the latter (

P

0.05). But there was no significant difference in the neural psychological cognitive assessment scales between the 2 groups (

P

0.05).       Conclusion      Controlling HbA1c under 7% delays the damage of type 2 diabetes in cognitive function. The application of insulin

no matter of human insulin or insulin analog

has a protective effect in the cognitive function of type 2 diabetes.